Literature DB >> 15184539

Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation.

Andrew McDowell1, Eshwar Mahenthiralingam1, Kerstin E A Dunbar1, John E Moore1, Mary Crowe1, J Stuart Elborn1.   

Abstract

Studies of the prevalence of Burkholderia cepacia complex species amongst cystic fibrosis (CF) patients in different geographical regions, and the association between cross-infection and putative transmissibility markers, will further our understanding of these organisms and help to address infection-control issues. In this study, B. cepacia complex isolates from CF patients in different regions of Europe were analysed. Isolates were examined for B. cepacia complex species and putative transmissibility markers [cable pilin subunit gene (cblA) and the B. cepacia epidemic strain marker (BCESM)]. Sporadic and cross-infective strains were identified by random amplification of polymorphic DNA (RAPD). In total, 79% of patients were infected with Burkholderia cenocepacia (genomovar III), 18% with Burkholderia multivorans (genomovar II) and less than 5% of patients with B. cepacia (genomovar I), Burkholderia stabilis (genomovar IV) or Burkholderia vietnamiensis (genomovar V). The cblA and BCESM transmissibility markers were only detected in strains of B. cenocepacia. The BCESM was a more sensitive marker for transmissible B. cenocepacia strains than cblA, although sporadic B. cenocepacia strains containing the BCESM, but lacking cblA, were also observed. Furthermore, clusters of cross-infection with transmissibility marker-negative strains of B. multivorans were identified. In conclusion, B. cenocepacia was the greatest cause of cross-infection, and the most widely distributed B. cepacia complex species, within these CF populations. However, cross-infection was not exclusive to B. cenocepacia and cblA and the BCESM were not absolute markers for transmissible B. cenocepacia, or other B. cepacia complex strains. It is therefore suggested that CF centres cohort patients based on the presence or absence of B. cepacia complex infection and not on the basis of transmissibility marker-positive B. cenocepacia as previously suggested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184539     DOI: 10.1099/jmm.0.45557-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  23 in total

1.  Unusual distribution of Burkholderia cepacia complex species in Danish cystic fibrosis clinics may stem from restricted transmission between patients.

Authors:  Niels Nørskov-Lauritsen; Helle Krogh Johansen; Mette G Fenger; Xiaohui C Nielsen; Tacjana Pressler; Hanne V Olesen; Niels Høiby
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting.

Authors:  A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-01       Impact factor: 3.267

3.  Identification and management of unusual pathogens in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

4.  Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis-Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection.

Authors:  Siobhán McClean; Marc E Healy; Cassandra Collins; Stephen Carberry; Luke O'Shaughnessy; Ruth Dennehy; Áine Adams; Helen Kennelly; Jennifer M Corbett; Fiona Carty; Laura A Cahill; Máire Callaghan; Karen English; Bernard P Mahon; Sean Doyle; Minu Shinoy
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

5.  Identification of the flagellin glycosylation system in Burkholderia cenocepacia and the contribution of glycosylated flagellin to evasion of human innate immune responses.

Authors:  Anna Hanuszkiewicz; Paula Pittock; Fiachra Humphries; Hermann Moll; Amanda Roa Rosales; Antonio Molinaro; Paul N Moynagh; Gilles A Lajoie; Miguel A Valvano
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

Review 6.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

7.  The Essential Genome of Burkholderia cenocepacia H111.

Authors:  Steven Higgins; Maria Sanchez-Contreras; Stefano Gualdi; Marta Pinto-Carbó; Aurélien Carlier; Leo Eberl
Journal:  J Bacteriol       Date:  2017-10-17       Impact factor: 3.490

8.  Characterization of the cciIR quorum-sensing system in Burkholderia cenocepacia.

Authors:  Rebecca J Malott; Adam Baldwin; Eshwar Mahenthiralingam; Pamela A Sokol
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

9.  Refractory Burkholderia cepacia bacteraemia from a consolidation pneumonia lasting more than 7 weeks, successfully treated with systemic antibiotics and nebulised meropenem.

Authors:  Bryan Albert Lim; Adelaine Lopez; Joseph Adrian Buensalido
Journal:  BMJ Case Rep       Date:  2019-08-02

10.  Susceptibility of Caenorhabditis elegans to Burkholderia infection depends on prior diet and secreted bacterial attractants.

Authors:  Vaughn S Cooper; Wendy A Carlson; John J Lipuma
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.